Present and future cell therapies for pancreatic beta cell replenishment

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

If only at a small scale, islet transplantation has successfully addressed what ought to be the primary endpoint of any cell therapy: the functional replenishment of damaged tissue in patients. After years of less-thanoptimal approaches to immunosuppression, recent advances consistently yield long-term graft survival rates comparable to those of whole pancreas transplantation. Limited organ availability is the main hurdle that stands in the way of the widespread clinical utilization of this pioneering intervention. Progress in stem cell research over the past decade, coupled with our decades-long experience with islet transplantation, is shaping the future of cell therapies for the treatment of diabetes. Here we review the most promising avenues of research aimed at generating an inexhaustible supply of insulin-producing cells for islet regeneration, including the differentiation of pluripotent and multipotent stem cells of embryonic and adult origin along the beta cell.

Original languageEnglish
Pages (from-to)6876-6884
Number of pages9
JournalWorld Journal of Gastroenterology
Volume18
Issue number47
DOIs
StatePublished - Dec 1 2012

Fingerprint

Islets of Langerhans Transplantation
Insulin-Secreting Cells
Cell- and Tissue-Based Therapy
Multipotent Stem Cells
Stem Cell Research
Pancreas Transplantation
Pluripotent Stem Cells
Graft Survival
Islets of Langerhans
Immunosuppression
Regeneration
Survival Rate
Insulin
Research
Therapeutics

Keywords

  • Beta cell differentiation
  • Human embryonic stem cells
  • Induced pluripotent stem cells
  • Islet transplantation
  • Mesenchymal stem cells
  • Reprogramming

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Present and future cell therapies for pancreatic beta cell replenishment. / Dominguez-Bendala, Juan; Ricordi, Camillo.

In: World Journal of Gastroenterology, Vol. 18, No. 47, 01.12.2012, p. 6876-6884.

Research output: Contribution to journalArticle

@article{62bd3153ece64621a37a065799692ec8,
title = "Present and future cell therapies for pancreatic beta cell replenishment",
abstract = "If only at a small scale, islet transplantation has successfully addressed what ought to be the primary endpoint of any cell therapy: the functional replenishment of damaged tissue in patients. After years of less-thanoptimal approaches to immunosuppression, recent advances consistently yield long-term graft survival rates comparable to those of whole pancreas transplantation. Limited organ availability is the main hurdle that stands in the way of the widespread clinical utilization of this pioneering intervention. Progress in stem cell research over the past decade, coupled with our decades-long experience with islet transplantation, is shaping the future of cell therapies for the treatment of diabetes. Here we review the most promising avenues of research aimed at generating an inexhaustible supply of insulin-producing cells for islet regeneration, including the differentiation of pluripotent and multipotent stem cells of embryonic and adult origin along the beta cell.",
keywords = "Beta cell differentiation, Human embryonic stem cells, Induced pluripotent stem cells, Islet transplantation, Mesenchymal stem cells, Reprogramming",
author = "Juan Dominguez-Bendala and Camillo Ricordi",
year = "2012",
month = "12",
day = "1",
doi = "10.3748/wjg.v18.i47.6876",
language = "English",
volume = "18",
pages = "6876--6884",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "47",

}

TY - JOUR

T1 - Present and future cell therapies for pancreatic beta cell replenishment

AU - Dominguez-Bendala, Juan

AU - Ricordi, Camillo

PY - 2012/12/1

Y1 - 2012/12/1

N2 - If only at a small scale, islet transplantation has successfully addressed what ought to be the primary endpoint of any cell therapy: the functional replenishment of damaged tissue in patients. After years of less-thanoptimal approaches to immunosuppression, recent advances consistently yield long-term graft survival rates comparable to those of whole pancreas transplantation. Limited organ availability is the main hurdle that stands in the way of the widespread clinical utilization of this pioneering intervention. Progress in stem cell research over the past decade, coupled with our decades-long experience with islet transplantation, is shaping the future of cell therapies for the treatment of diabetes. Here we review the most promising avenues of research aimed at generating an inexhaustible supply of insulin-producing cells for islet regeneration, including the differentiation of pluripotent and multipotent stem cells of embryonic and adult origin along the beta cell.

AB - If only at a small scale, islet transplantation has successfully addressed what ought to be the primary endpoint of any cell therapy: the functional replenishment of damaged tissue in patients. After years of less-thanoptimal approaches to immunosuppression, recent advances consistently yield long-term graft survival rates comparable to those of whole pancreas transplantation. Limited organ availability is the main hurdle that stands in the way of the widespread clinical utilization of this pioneering intervention. Progress in stem cell research over the past decade, coupled with our decades-long experience with islet transplantation, is shaping the future of cell therapies for the treatment of diabetes. Here we review the most promising avenues of research aimed at generating an inexhaustible supply of insulin-producing cells for islet regeneration, including the differentiation of pluripotent and multipotent stem cells of embryonic and adult origin along the beta cell.

KW - Beta cell differentiation

KW - Human embryonic stem cells

KW - Induced pluripotent stem cells

KW - Islet transplantation

KW - Mesenchymal stem cells

KW - Reprogramming

UR - http://www.scopus.com/inward/record.url?scp=84873912337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873912337&partnerID=8YFLogxK

U2 - 10.3748/wjg.v18.i47.6876

DO - 10.3748/wjg.v18.i47.6876

M3 - Article

VL - 18

SP - 6876

EP - 6884

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 47

ER -